The impact of commonly used diabetes and cardiovascular therapies, such as metformin, statins, SGLT2 inhibitors, and GLP-1 receptor agonists, on checkpoint signaling remains insufficiently understood, and clarifying these interactions is essential for developing rational therapeutic combinations. Here, GLP1R is linked to diabetes mellitus.